Literature DB >> 20172612

Antibodies to gangliosides and ganglioside complexes in Guillain-Barré syndrome and Fisher syndrome: mini-review.

Kenichi Kaida1, Susumu Kusunoki.   

Abstract

Antiganglioside antibodies play a pathogenic role in the pathophysiology of Guillain-Barré syndrome (GBS) and Fisher syndrome (FS). Antiganglioside antibody-mediated nerve injury is likely to result from nerve damage through complement activation or dysfunction of molecules such as voltage-gated sodium and calcium channels. Clustered epitopes of complexes of two gangliosides in the cell membrane can be targeted by serum antibodies in GBS and FS and may regulate the accessibility and avidity of antiganglioside antibodies. The glycolipid environment or the specific distribution of target gangliosides in the peripheral nervous system may also influence the pathogenic effect of antiganglioside antibodies in GBS and FS. Structural and functional analyses of glycoepitopes of ganglioside complexes in membranes will provide new vistas on antibody-antigen interaction in GBS and shed light on microdomain function mediated by carbohydrate-carbohydrate interactions, which may lead to novel treatments for GBS and FS. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20172612     DOI: 10.1016/j.jneuroim.2010.02.001

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  23 in total

1.  Cerebrospinal fluid under non-steady state condition caused by plasmapheresis.

Authors:  Dominik Madžar; Christian Maihöfner; Rüdiger Zimmermann; Stefan Schwab; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2010-11-16       Impact factor: 3.575

2.  Fisher syndrome.

Authors:  Masahiro Mori; Satoshi Kuwabara
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

3.  Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy.

Authors:  F Galban-Horcajo; A M Fitzpatrick; A J Hutton; S M Dunn; G Kalna; K M Brennan; S Rinaldi; R K Yu; C S Goodyear; H J Willison
Journal:  Eur J Neurol       Date:  2012-06-22       Impact factor: 6.089

Review 4.  Progress in inflammatory neuropathy -the legacy of Dr Jack Griffin.

Authors:  Eva L Feldman; Richard A C Hughes; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2015-10-13       Impact factor: 42.937

Review 5.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

Review 6.  Guillain-barré syndrome: modern theories of etiology.

Authors:  Todd A Hardy; Stefan Blum; Pamela A McCombe; Stephen W Reddel
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

Review 7.  Crosstalk between the nociceptive and immune systems in host defence and disease.

Authors:  Stephen B McMahon; Federica La Russa; David L H Bennett
Journal:  Nat Rev Neurosci       Date:  2015-07       Impact factor: 34.870

Review 8.  Immunotherapy of Guillain-Barré syndrome.

Authors:  Shuang Liu; Chaoling Dong; Eroboghene Ekamereno Ubogu
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

9.  First case of anti-ganglioside GM1-positive Guillain-Barré syndrome due to hepatitis E virus infection.

Authors:  I Maurissen; A Jeurissen; T Strauven; D Sprengers; B De Schepper
Journal:  Infection       Date:  2011-08-30       Impact factor: 3.553

Review 10.  Immunoglobulin-mediated neuro-cognitive impairment: new data and a comprehensive review.

Authors:  Assaf Menachem; Joab Chapman; Yael Deri; Chaim G Pick; Aviva Katzav
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.